ADMA Biologics
ADMA Mid CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
ADMA Biologics Stock at a Glance
ADMA Biologics (ADMA) is currently trading at 8,97 € with a market capitalization of 2,1 Mrd. €. The trailing P/E ratio stands at 17.53x, with a forward P/E of 8.33x. The 52-week range spans from 6,15 € to 20,62 €; the current price is 56.5% below the yearly high. Year-over-year revenue growth stands at +15.9%. The net profit margin stands at 28.8%.
💰 Dividendo
ADMA Biologics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
3 analysts rate ADMA Biologics (ADMA) on consensus: Acquisto Forte. The average price target is 17,63 €, implying +96.45% from the current price. Analyst price targets range from 14,50 € to 20,47 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Profitable with 28.8% net margin
- High return on equity (35.56% ROE)
- High gross margin of 57.38% — indicates pricing power
- Analyst consensus: Strong Buy
- –High short interest (10.16%)
- –Negative free cash flow
Panoramica Tecnica
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profilo di Rischio
The data points to relatively defensive market behavior, elevated short interest (10.16%), higher leverage relative to equity.
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy ADMA Biologics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
